±³¾°
ÅÁ½ðɲ¡£¨Parkinson¡¯s disease, PD£©ÊdzýÁËÕâ¸ö²¡Ö®Í⣬ÊÀ½çµÚ¶þ´óµÄÉñ¾ÍËÐÐÐÔ¼²²¡¡£ÎªÁ˼ÍÄî·¢ÏÖÕâÒ»¼²²¡µÄÓ¢¹úÒ½Éúղķ˹¡¤ÅÁ½ðÉ£¬ÈËÃǽ«ËûµÄÉúÈÕ¡ª¡ª4ÔÂ11ÈÕÈ·¶¨Îª¡°ÊÀ½çÅÁ½ðÉÈÕ¡±¡£
ÅÁ½ðɲ¡µÄÖ÷ÒªÖ¢×´±íÏÖΪÔ˶¯Õϰ£¬ÈçÔ˶¯³Ù»º£¨bradykinesia£©¡¢½©Ö±£¨rigidity£©¡¢¾²Ö¹ÐÔÕð²ü£¨tremor£©µÈ¡£³ý´ËÖ®ÍâÅÁ½ðÉ»¼ÕßÒ²±íÏÖ³öÁ˸оõÕϰºÍÈÏÖª¹¦ÄÜÕϰµÈ·ÇÔ˶¯Ö¢×´¡£Ò»Ïî2016ÄêµÄÑо¿ÏÔʾ£¬60ËêÒÔÉÏÀÏÄêÈËȺÖÐÅÁ½ðɲ¡µÄ»¼²¡ÂÊԼΪ1%-2%£»¶øÔÚ80ËêÒÔÉÏÈËȺÖУ¬ÕâÒ»±ÈÀýÔò»áÉÏÉýÖÁ4%×óÓÒ1¡£Ä¿Ç°£¬ÎÒ¹úµÄÅÁ½ðÉ»¼ÕßÒѾ´ïµ½ÁË200ÍòÈË£¬Õ¼È«ÊÀ½çÅÁ½ðɲ¡È˵ÄÒ»°ë×óÓÒ¡£ÔÚÎÒ¹úÀÏÁ仯Öð²½¼ÓÉîµÄ±³¾°Ï£¬ÅÁ½ðɲ¡ÒѾ³ÉΪÍþвÀÏÄêÈËȺÉíÐĽ¡¿µµÄÒ»´ó¡°É±ÊÖ¡±¡£
ÅÁ½ðɲ¡×îΪͻ³öµÄ²¡Àí¸Ä±äÊÇÖÐÄÔºÚÖÊÖжà°Í°·ÄÜÉñ¾ÔªµÄ±äÐÔºÍËÀÍö¡£ÁíÍâÈËÃÇ·¢ÏÖ£¬²Ð´æÉñ¾ÔªÖзÒ×СÌåµÄÐγɺͦÁ-Í»´¥ºËµ°°×µÄ¾Û¼¯Ò²ÊÇÅÁ½ðɲ¡µÄµäÐÍÌØÕ÷Ö®Ò»¡£ÅÁ½ðɲ¡µÄ²¡ÒòÖÁ½ñδÃ÷£¬Ö¤¾ÝÏÔʾÒÅ´«¡¢»·¾³ÎÛȾ¡¢Ë¥ÀϵÈÒòËØ¾ùÔÚÅÁ½ðɲ¡µÄ·¢ÉúÖаçÑÝÁËÒ»¶¨µÄ½ÇÉ«¡£
ΪÁËÑо¿ÅÁ½ðɲ¡µÄ·¢²¡ÔÒòÒÔ¼°Ì½Ë÷еÄÁÙ´²µÄÖÎÁÆÊֶΣ¬ÖƱ¸ÓÐЧµÄÅÁ½ðɲ¡¶¯ÎïÄ£ÐÍÓÐ×ÅÖØÒªµÄÒâÒå¡£ÔÚ±¾ÎÄÖÐÎÒÃǽ«½éÉÜ3ÖÖÖ÷Á÷µÄÅÁ½ðɲ¡µÄ¶¯ÎïÄ£Ð͵ÄÔÀíºÍÖÆ±¸·½·¨¡£¶øÔÚÏÂÆÚ£¬ÎÒÃǽ«½éÉܼìÑé´óСÊóÅÁ½ðÉÄ£ÐÍÔìģЧ¹ûµÄ²¡ÀíºÍÐÐΪѧ·½·¨¡£
1.MPTPÓÕµ¼Ð¡ÊóÅÁ½ðÉÄ£ÐÍ
1982Ä꣬7¸öÀ´×Ô¼ÓÀû¸£ÄáÑÇÖÝÊ¥¿ËÀÀÏØµÄ¡°æÒƤʿ¡±ÔÚÎüʳÁËÒ»Öֺϳɺ󱻽ô¼±ËÍÍùÒ½Ôº¾ÈÖΡ£Ò½Éú¾ªÆæµØ·¢ÏÖ£¬Õâ7λ»¼ÕßËäÈ»Äê¼ÍÇáÇᣬÐж¯È´Ïñ°ÙËêÀÏÈËÒ»Ñù³Ù»º£¬²¢°éËæÓÐÖ«ÌåÕð²üµÄÏÖÏ󣬺ÍÅÁ½ðɲ¡µÄ±íÏÖÊ®·ÖÏàËÆ¡£½øÒ»²½µÄ¼ìÑé±íÃ÷£¬ÕâÅúºÏ³ÉÖк¬ÓÐÒ»ÖÖÃûΪ1-¼×»ù-4-±½»ù-1,2,3,6-ËÄÇâßÁण¨1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,
MPTP£©µÄÔÓÖÊ2¡£1984Ä꣬˹̹¸£´óѧµÄÉñ¾Ñ§¼ÒÍþÁ®¡¤À¼Ë¹¶ÙÈ·ÈÏMPTPÕýÊǵ¼ÖÂÕâЩÄêÇáÈ˳öÏÖÅÁ½ðÉÑùÖ¢×´µÄ×ï¿ý»öÊ×3¡£
´ÓÔÀíÀ´¿´£¬MPTP±¾Éí¶Ôϸ°û²¢ÎÞ¶¾º¦×÷Óᣵ«Êǵ±MPTP½øÈëÌåÄÚºó£¬ÓÉÓÚ×ÔÉíÁ¼ºÃµÄÖ¬ÈÜÐÔ£¬MPTP¿ÉÒÔÇáÒ×´©¹ýѪÄÔÆÁÕÏ£¨blood-brain barrier,
BBB£©½øÈëÖÐÊàÉñ¾ÏµÍ³4¡£¶øÔÚÄÔÖУ¬MPTP»á±»Éñ¾½ºÖÊϸ°ûÖеĵ¥°·Ñõ»¯Ã¸B£¨MAO-B£©´úлΪһÖÖÃûΪMPDP +µÄÖмäÌå¡£¶ø¸ÃÖмäÌåÔÙ¾¹ý½øÒ»²½µÄÑõ»¯£¬×îÖÕÐγÉÓж¾µÄ´úлÎï¼×»ù-±½»ùËÄÇâßÁà¤æfÑΣ¨MPP +£©5¡£
MPP+µÄ½á¹¹½Ó½ü¶à°Í°·£¬Òò´Ë»á´íÎ󵨱»ÖÐÄÔ¶à°Í°·Éñ¾ÔªÄ¤ÉϵĶà°Í°·×ªÔËÌ壨dopamine transporter,
DAT£©Ñ¡ÔñÐÔÖØÎüÊÕ½øÈëϸ°ûÄÚ6¡£¶øÒ»µ©½øÈëϸ°û£¬MPP+Ôò»á¡°Ð×Ïà±Ï¶¡±£¬Ëü»áÒÖÖÆÏßÁ£ÌåºôÎüÁ´¸´ºÏÌåIµÄ»îÐÔ7£¬´Ó¶ø×è¶Ïµç×Ó×ªÒÆÁ´£¬¼õÉÙATPµÄÉú³É²¢´Ù½ø»îÐÔÑõ(reactive oxygen species,
ROS)µÄ²úÉú£¬×îÖÕÔì³ÉÉñ¾ÔªµÄËðÉË8¡£
ͼ1 MPTPµÄ´úл;¾¶ºÍMPP+ÔÚ°ûÄڵķ¾¶
ÕýÒòΪMPTPÊǵÚÒ»¸öÒ²ÊÇĿǰÄܹ»ÔÚÈËÀàÉíÉϸ´ÏÖÅÁ½ðÉÖ¢×´µÄÉñ¾¶¾ËØ£¨Ä³ÖÖÒâÒåÉÏ»¹Òª¸ÐлÕ⼸λ¼ÓÖݵÄÄêÇáÈË£©£¬MPTPÓÕµ¼µÄÅÁ½ðÉÄ£ÐͳÉΪÁËÔÚģʽ¶¯ÎïÉÏÑо¿ÅÁ½ðɲ¡ÁÙ´²ÁÆ·¨µÄ¡°½ð±ê×¼¡±£¬ÓÈÆäÊÇMPTPÓÕµ¼µÄ·ÇÈËÁ鳤ÀࣨÈçºãºÓºï£©ÅÁ½ðÉÄ£ÐÍ¡£¶øMPTPÓÕµ¼µÄСÊóÅÁ½ðÉÄ£ÐÍÓÉÓÚÔìÄ£¼¼ÊõÏà¶Ô¼òµ¥£¨Ö»ÐèÒª¸¹Ç»×¢É䣩¡¢¶Ô¶à°Í°·Éñ¾ÔªµÄɱÉËЧ¹ûÎȶ¨Ò²µÃµ½Á˹㷺µÄÈϿɡ£²»ÉÙ¹ØÓÚ¶à°Í°·ÄÜÉñ¾ÔªËÀÍö»úÖÆ·½ÃæµÄÑо¿¶¼²ÉÓÃMPTPÓÕµ¼µÄСÊóÅÁ½ðÉÄ£ÐÍ×÷ΪʵÑ鷶ʽ¡£
¶¯ÎÐÛÐÔC57BL/6£¬´óÔ¼7-8ÖÜÁ䣬ÌåÖØ25-30 g¡£×¢ÒâMPTPÓÕµ¼µÄСÊóÅÁ½ðÉÄ£ÐͶԶ¯ÎïµÄÐÔ±ð¡¢ÌåÖØ¡¢ÄêÁäÉõÖÁƷϵÀ´Ô´£¨ÊÇJackson lab»¹ÊÇCharles
River£©¾ù·Ç³£Ãô¸Ð¡£ÔÚÌôÑ¡¶¯ÎïµÄʱºòҪʮ·ÖСÐÄ¡£
ËÇÑø£º¶©¹ºµÄ¶¯Îﵽλºó£¬ÔÚ×¢ÉäǰÎñ±ØÊÊÓ¦ÐÔËÇÑø1ÖÜ×óÓÒ¡£ÒòΪ³¤¾àÀëÔËÊä»á¸Ä±äÄÔµÄ״̬£¬Òò´ËÐèÒª5-7Ììʱ¼äÀ´Ê¹¶¯Îï»Ö¸´²¢ÊÊÓ¦»·¾³¡£
×¢É䣺ÔÚ×¢Éäµ±ÌìÅäÖÆºÃÐÂÏʵÄMPTPÈÜÒº£¬È»ºóÿֻ¶¯Îï°´14-20 mg/kgÌåÖØµÄ¼ÁÁ¿¸¹Ç»×¢ÉäMPTP¡£¼ä¸ô2Сʱºó½øÐÐÏÂÒ»´Î×¢É䣬µ±Ìì¹²½øÐÐ4´Î×¢Éä¡£
Êõºó»¤Àí£º×¢ÉäÖ®ºó´óÔ¼30·ÖÖÓ£¬Ð¡Êó¾Í»á³öÏÖÀàËÆÅÁ½ðɵÄÖ¢×´£¬Èçǿֱ»òÕð²üµÈ¡£¶øÔÚ´óÔ¼3Сʱºóδ±»´úлµÄMPTP½«»áËæ×Ŷ¯ÎïµÄÅÅйÎï±»Êͷŵ½µæÁÏÖС£Òò´ËÔÚ×¢ÉäÖ®ºóСÊóÐèÒª½øÐÐÑϸñµÄ¸ôÀëËÇÑø¡£ÆäʹÓõĵæÁÏ¡¢ÒûË®±ØÐë¾¹ýÎÞº¦»¯´¦Àí£¬È»ºó×÷ΪҽÁÆÀ¬»ø·ÏÆú¡£´óÔ¼3-4Öܺó¿ÉÒÔ¶Ô¶¯ÎïµÄ²¡ÀíºÍÐÐΪ±íÏÖ½øÐмì²â¡£
2.6-OHDAÓÕµ¼ÅÁ½ðÉÄ£ÐÍ
6-ôǶà°Í°·£¨6-hydroxydopamine,
6-OHDA£©ÊǶà°Í°·µÄôÇ»ù»¯ÑÜÉúÎÓÚ1959ÄêÊ×Ïȱ»SenohµÈÈ˳ɹ¦·ÖÀë9¡£×Ô·¢ÏÖÒÔÀ´µÄ°ë¸ö¶àÊÀ¼ÍÖУ¬6-OHDAÒ»Ö±ÔÚÅÁ½ðɲ¡µÄÁÙ´²Ç°Ñо¿ÖаçÑÝ×ÅÖØÒª½ÇÉ«¡£ÓÉUngerstedtºÍArbuthnottÔÚ1970Ä깲ͬ´´Á¢µÄµ¥²à×¢ÉäÐýתģÐͳÉΪÁËÔÚģʽ¶¯ÎïÉϱ»×îΪ¹ã·ºÊ¹ÓõÄÅÁ½ðÉÄ£ÐÍÖ®Ò»10¡£
6-OHDA¶ÔÉñ¾ÔªµÄ¶¾º¦×÷ÓÃÓÐÒ»¸ö¡°Á½²½×ß¡±µÄ¹ý³Ì¡£µÚÒ»²½ÊÇÌØÒìÐÔµØÔÚ¶à°Í°·ÄÜÉñ¾ÔªÄڵĻýÀÛ¡£ÓÉÓÚ6-OHDAµÄ½á¹¹ºÍ¶ù²è·Ó°·ÀàËÆ£¬Òò´ËÊÍ·ÅÔÚϸ°û¼äÖÊÖеÄ6-OHDA»á±»¶à°Í°·Éñ¾Ôª°ûÌå»òÍ»ÆðÉϵĶà°Í°·×ªÔËÌå´íÎóµØÊ¶±ð²¢ÖØÎüÊÕ½øÈëϸ°û£¨Í¼2£©¡£µÚ¶þ²½ÔòÊÇϸ°û¶¾ÐÔ¡£µ±6-OHDA½øÈëÉñ¾Ôªºó£¬Ò»·½Ã潫»á±»µ¥°·Ñõ»¯Ã¸-A£¨MAO-A£©´ß»¯ÐγɹýÑõ»¯Ç⣨H2O2£©¡£¹ýÑõ»¯Çâ±¾Éí¾ßÓкÜÇ¿µÄϸ°û¶¾ÐÔ£¬Í¬Ê±Ò²»á´¥·¢Ñõ×ÔÓÉ»ùµÄÐγÉ12¡£¶øÁíÒ»·½Ã棬×Ô¶¯Ñõ»¯£¨autooxidation£©×÷ÓÃËù´óÁ¿²úÉúµÄ»îÐÔÑõºÍõ«Àà²úÎﳬ³öÁËϸ°ûÄÚ¿¹Ñõ»¯Ã¸µÄ³ÐÊÜÄÜÁ¦£¬µ¼ÖÂϸ°û½á¹¹ºÍ´úлµÄÎÉÂÒ£¬×îÖÕ½á¹û¾ÍÊÇÉñ¾ÔªµÄËðÉË£¨Í¼2£©¡£
ͼ2 6-OHDA½éµ¼µÄÉñ¾¶¾ÐÔ×÷ÓûúÖÆ
ÓëMPTP²»Í¬µÄÊÇ£¬6-OHDA²¢²»ÄÜ´©Í¸ÑªÄÔÆÁÕÏ¡£Òò´ËΪÁË´ïµ½ÖÐÊàÉñ¾ÏµÍ³»ÙÉ˵ÄЧ¹û£¬ÔÚʹÓÃ6-OHDA½øÐÐÅÁ½ðÉÔìģʱÐèҪʹÓÃÄÔÁ¢Ì嶨λעÉä¼¼Êõ½«6-OHDA×¢Èëµ½ºÚÖÊ-ÎÆ×´Ì壨striatonigral£©ÕâÒ»¶à°Í°·ÄÜͶÉäͨ·ÖС£¾ßÌåµÄ×¢Éäλµã¿ÉÒÔÊǺÚÖÊÖÂÃܲ¿£¨substantia
nigra pars compacta, SNpc£©¡¢ÎÆ×´Ì壨striatum£©»òÕßλÓÚ¶þÕßÖ®¼äµÄǰÄÔÄÚ²àÊø£¨MFB£©¡£
¶¯Î6-8ÖÜÁäµÄC57/BLСÊ󣬴ÆÐÛ²»ÏÞ£¬ÌåÖØ20-25 g×óÓÒ¡£
ËÇÑø£ºÓëMPTPÓÕµ¼µÄÄ£ÐÍÏàͬ£¬¶¯Îï¶©¹ºÖ®ºóÐèÒªÖÁÉÙÊÊÓ¦ÐÔËÇÑø1ÖܺóÔÙ½øÐÐÔìÄ£ÊÖÊõ¡£
ÄÔ¶¨Î»×¢É䣺ÔÚ33GµÄHamilton×¢ÉäÆ÷»ò²£Á§µç¼«ÖÐÔ¤ÏÈÎüÈë1 ¦ÌL×óÓÒŨ¶ÈΪ3
¦Ìg/mLµÄ6-OHDAÈÜÒº¡£Ð¡ÊóÂé×íºó¹Ì¶¨ÔÚÄÔÁ¢Ì嶨λÒÇÉÏ¡£¼ô¿ªÍ·Æ¤ºóÓÃÃÞÇ©ÇáÇá²ÁÊùDZíÃæ½«Ç°Ø¶£¨bregma£©ºÍºóض£¨lambda£©µã±©Â¶³öÀ´¡£µ÷½ÚÁ¢Ì嶨λÒÇ£¬½«Ç°Ø¶ºÍºóضµãµÄ¸ß¶Èµ÷½Úµ½Ò»Ö´ӶøÊ¹Â¹Ç±£³Öˮƽ¡£ÒÔbregmaµãΪԵ㣬ÕÒµ½×¢ÉäλµãËùÔÚµÄ×ø±ê£¬ÓÃÑÀ¿Æ×꽫עÉäλµãÉÏ·½µÄ¹Ç×꿪һ¸öС¶´¡£ÔÚ6-OHDAÓÕµ¼µÄÄ£ÐÍÖУ¬×¢Éäλµã¿ÉÒÔÊǺÚÖÊ£¨AP
-2.90 mm; ML +1.10 mm; DV -4.50 mm£©£¬Ò²¿ÉÒÔÊÇǰÄÔÄÚ²àÊø£¨AP -1.20 mm; ML +1.10 mm; DV -5.00 mm£©»òÎÆ×´Ì壨AP +0.2 mm; ML ¡À2.00 mm; DV
-2.60 mm£©¡£½«²£Á§µç¼«»ò×¢ÉäÕ뻺Âý²åÈë×¢Éäλµã£¬ÒÔ0.2 ¦ÌL/minµÄËٶȽ«6-OHDA×¢É䵽Ŀ±êÄÔÇø¡£×¢Éä½áÊøºó£¬×¢ÉäÕëÓ¦¸Ã¼ÌÐøÍ£ÁôÔÚ×¢Éäλµã5·ÖÖÓ×óÓÒÒÔʹҩÎïÄܹ»³ä·ÖÀ©É¢¡£ÌáÆð×¢ÉäÕ룬½«¶¯ÎïµÄͷƤ·ìºÏ²¢Ïû¶¾¡£
Êõºó»¤Àí£ºÄÔ¶¨Î»×¢ÉäÍê³Éºó½«¶¯Îï·ÅÔÚ¼ÓÈȰå»òµÆ¹âÏÂÕÕÉä±£³ÖÌåΡ£´ý¶¯ÎïËÕÐѺó·Å»ØÁýÖС£Êõºó3ÌìÄÚÿÌ츹ǻעÉäÒ»´Î¿¹ÉúËØ¡£´óÔ¼3-4Öܺó¿ÉÒÔ½øÐÐÐÐΪѧ¼ì²â¡£
3.»ùÓÚ¦Á-Í»´¥ºËµ°°×µÄÄ£ÐÍ
³ýÁ˶à°Í°·Éñ¾Ôª¶ªÊ§Ö®Í⣬ÅÁ½ðɲ¡µÄÁíÒ»ÖÖµäÐ͵ÄÉñ¾²¡Àí±êÖ¾ÊDzдæµÄÉñ¾Ôª°ûÖÊÄÚ³öÏÖÒ»ÖÖÊÈËáÐԵİüºÌ壬¼´Â·Ò×СÌ壨Lewy bodies,
LBs£©¡£ÏÔ΢¾µÏ³ÊÏÖÔ²ÐεķۺìÉ«¾ùÖʽṹ¡£Â·Ò×СÌåµÄÖ÷Òª×é³É³É·ÖÊÇÒ»ÖÖ½Ð×ö¦Á-Í»´¥ºËµ°°×£¨¦Á-synuclein,
¦Á-Syn£©µÄÍ»´¥Ç°µ°°×¡£´óÁ¿Ö¤¾ÝÏÔʾ£¬¦Á-Í»´¥ºËµ°°×µÄ¾Û¼¯ºÍ·Ò×СÌåµÄÐγÉÓë¶à°Í°·Éñ¾ÔªµÄËÀÍöÓÐ×ÅÃÜÇеÄÁªÏµ13¡£
¦Á-Í»´¥ºËµ°°×ÓÉSNCA»ùÒò±àÂ룬ÊÇÒ»ÖÖÖ÷Òª±í´ïÔÚÍ»´¥Ç°ºÍºËÖܵĿÉÈÜÐÔµ°°×¡£¦Á-Í»´¥ºËµ°°×µÄÈ·Çй¦ÄÜÖÁ½ñÈÔ²»Çå³þ£¬²»¹ýÓÐÖ¤¾ÝÏÔʾ¿ÉÄÜÓëÍ»´¥¿ÉËÜÐÔ»òÉñ¾µÝÖÊÊÍ·ÅÏà¹Ø¡£Õý³£×´Ì¬ÏµĦÁ-Í»´¥ºËµ°°×ÒÔµ¥Ì壨monomers£©»òÕߦÁÂÝÐý×´£¨¦Á-helical£©ÕÛµþµÄËľÛÌåÐÎʽ´æÔÚ£¬¿ÉÈܲ¢ÇÒÏÊÓоۼ¯µÄÇé¿ö£»µ«ÔÚ²¡Àí״̬Ï£¬¦Á-Í»´¥ºËµ°°×»á¸Ä±ä¹¹ÏóΪ¸»º¬¦ÂƬ״£¨¦Â-sheet£©ÕÛµþµÄ½á¹¹¡£´íÎóÕÛµþµÄ¦Á-Í»´¥ºËµ°°×»á¾Û¼¯ÆðÀ´ÐγɹѾÛÌ壬²¢Öð½¥ÏòÏËάԺͲ»ÈÜÐÔÏËάµÄÐÎ̬·¢Õ¹£¬×îÖÕ³Á»ýÔÚ·Ò×СÌåÖС£³ý´ËÖ®Í⣬´óÁ¿Ñо¿Ö¤¾Ý±íÃ÷£¬´íÎóÕÛµþµÄ¦Á-Í»´¥ºËµ°°×¿ÉÒÔ±íÏÖ³öëò¡¶¾£¨prion£©µÄÐÔÖÊ£¬ÓÕ·¢ÄÚÔ´¦Á-Í»´¥ºËµ°°×µÄ´íÎóÕÛµþºÍ¾Û¼¯£¬²¢Í¨¹ýϸ°û¼ä´«µÝµÄ·½Ê½ÔÚÉñ¾ÔªÖ®¼äÀ©É¢¡£
Ïà±ÈÓÚʹÓÃÉñ¾¶¾ËØÉ±É˶à°Í°·Éñ¾ÔªµÄÅÁ½ðÉÄ£ÐÍ£¬»ùÓÚ¦Á-Í»´¥ºËµ°°×µÄÅÁ½ðɲ¡Ä£ÐÍÓÉÓÚÔÚʱ³ÌÉÏÄܹ»½ÏºÃµØÄ£ÄâÅÁ½ðɲ¡·¢Éú¡¢·¢Õ¹µÄÈ«¹ý³Ì£¬ÕâÓÐÀûÓÚ·¢ÏÖºÍʶ±ðеÄÖÎÁưе㡣ÔÚÖî¶à»ùÓÚ¦Á-Í»´¥ºËµ°°×µÄÅÁ½ðÉÄ£ÐÍÖУ¬½üÄêÀ´±»×î¹ã·ºÊ¹ÓõÄÄ£ÐÍ¿ÉÒÔ¹éÄÉΪ2ÖÖ£ºÔ¤ÖÆÏËά£¨pre-performed
fibrils, PFFs£©ºÍAAV²¡¶¾¿ÅÁ£Ä£ÐÍ¡£
ʹÓæÁ-Í»´¥ºËµ°°×µÄÔ¤ÖÆÏËά½øÐÐÔìÄ£Ê×ÏÈÐèÒªÖÆ±¸PFFs¡£¼ò¶øÑÔÖ®£¬Ô¤ÖÆÏËάÊ×ÏÈÔÚÌåÍâÓÉÖØ×éµÄ¦Á-Í»´¥ºËµ°°×µ¥ÌåÉú³É¡£½ÓÏÂÀ´£¬¾Û¼¯³ÉÔÏËάµÄ¦Á-Í»´¥ºËµ°°×±»ÌáÈ¡³öÀ´²¢³¬ÉùÆÆËéΪ¶ÌÏËάµÄÐÎʽ14¡£Ê¹ÓÃÄÔÁ¢Ì嶨λעÉäµÄ·½Ê½½«PFFs×¢Éä½øÄÔÄÚ£¬ÔÚ´óÔ¼12Öܺ󽫻áÓÕ·¢ÄÚÔ´¦Á-Í»´¥ºËµ°°×µÄ¾Û¼¯¡¢Á×ËữºÍ·ºËØ»¯·´Ó¦¡£
ÁíÒ»ÖÖÓÐЧµÄ·½Ê½ÊÇʹÓÃÖØ×éÏÙÏà¹Ø²¡¶¾£¨recombinant adeno-associated virus,
rAAV£©ÍâÔ´¹ý±í´ïÒ°ÉúÐÍ»òµãÍ»±äÐÍ£¨ÈçA53T£©¦Á-Í»´¥ºËµ°°×¡£ÖµµÃ×¢ÒâµÄµÄÊÇ£¬¹¹½¨AAVÔØÌå²ÉÓõÄѪÇåÐÍºÍÆô¶¯×Ó£¬ÒÔ¼°²¡¶¾×¢ÉäµÄµÎ¶ÈºÍ¼ÁÁ¿¶¼»á¶Ô¦Á-Í»´¥ºËµ°°×¹ý±í´ïµÄЧÂʲúÉúÓ°Ïì15¡£Ä¿Ç°µÄÑо¿ÏÔʾ£¬Ê¹Óó£ÓõÄCMV»òÕßhSynÆô¶¯×Ó¾ù¿ÉÒÔÌṩ¸ßˮƽµÄ»ùÒò±í´ïЧÂÊ¡£ÁíÍ⣬ʹÓÃһЩת¼ºóµ÷¿ØÔª¼þ£¬ÈçÍÁ²¦Êó¸ÎÑײ¡¶¾×ªÂ¼ºóµ÷½ÚÐòÁУ¨WPRE£©»òÕßpoly(A)β°ÍͬÑù¿ÉÒÔÏÔÖøÌá¸ßת»ùÒòµÄЧÂÊ¡£
¶¯Î6-8ÖÜÁäµÄC57/BLСÊó»òPDÏà¹ØµÄת»ùÒòÊ󣬴ÆÐÛ²»ÏÞ£¬ÌåÖØ20-25 g×óÓÒ¡£
ËÇÑø£º¶¯Îï¶©¹ºÖ®ºóÐèÒªÖÁÉÙÊÊÓ¦ÐÔËÇÑø1ÖܺóÔÙ½øÐÐÄÔ¶¨Î»×¢Éä¡£
ÄÔ¶¨Î»×¢É䣺ʹÓÃ10 ¦ÌL£¬33GµÄHamilton×¢ÉäÆ÷Ô¤ÏÈÎüÈë2.5 ¦ÌL×óÓÒ¦Á-Í»´¥ºËµ°°×PFFs£¬ÆäÖЦÁ-Í»´¥ºËµ°°×ÏËάµÄº¬Á¿Ô¼Îª5
¦Ìg¡£¶¯Î↑º͵÷ƽ²Ù×÷ÓÚ6-OHDA×¢ÉäÒ»Ö¡£¦Á-Í»´¥ºËµ°°×ͨ³£±»µ¥²à×¢ÉäÔÚÎÆ×´Ì壨AP +0.2 mm; ML ¡À2.00 mm; DV -2.60 mm£©¡£×¢ÉäÕ뻺Âý²åÈë×¢Éäλµã£¬ÒÔ0.1
¦ÌL/minµÄËٶȽ«PFFs×¢É䵽Ŀ±êÄÔÇø¡£×¢Éä½áÊøºó£¬×¢ÉäÕëÓ¦¸Ã¼ÌÐøÍ£ÁôÔÚ×¢Éäλµã5·ÖÖÓ×óÓÒÒÔʹÏËά³ä·ÖÀ©É¢¡£×îºóÌáÆð×¢ÉäÕ룬½«¶¯ÎïµÄͷƤ·ìºÏ²¢Ïû¶¾¡£
Èç¹ûÊDz¡¶¾×¢É䣬Ôò¹¹½¨AAV2/1-A53T(ÈËÀà¦Á-Í»´¥ºËµ°°×A53TµãÍ»±äÐÍ)-EGFP-WPRE²¡¶¾ÔØÌ壬ÓÃ×¢ÉäÆ÷»ò²£Á§µç¼«ÎüÈ¡1.5 ¦ÌL£¬µÎ¶ÈΪ2-3¡Á1012 v.g./mL²¡¶¾£¬²¢ÒÔ0.1
¦ÌL/minµÄËٶȵ¥²à×¢ÉäÔÚºÚÖÊ£¨AP -3.1 mm; ML -1.4 mm; DV -4.4 mm£©¡£
ͼ3 ÎÆ×´Ìå×¢ÉäµÄ×ø±êʾÒâͼ
Êõºó»¤Àí£ºÄÔ¶¨Î»×¢ÉäÍê³Éºó½«¶¯Îï·ÅÔÚ¼ÓÈȰå»òµÆ¹âÏÂÕÕÉä±£³ÖÌåΡ£´ý¶¯ÎïËÕÐѺó·Å»ØÁýÖС£Êõºó3ÌìÄÚÿÌ츹ǻעÉäÒ»´Î¿¹ÉúËØ¡£´óÔ¼90Ììºó¶¯Îï»áÖð½¥±íÏÖ³öÅÁ½ðɱíÐÍ¡£